tirzepatide surmount-1 nejm 2022 weight loss percent (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT-1 Tirzepatide Trial — 22.5%

L.RoddickA

Prompt medical help is the safest course of action

While medication is not a replacement for healthy lifestyle habits, tirzepatide can be a valuable adjunct for those who have struggled to achieve meaningful and sustained weight loss through diet and exercise alone

It alters the bodys response to food at the cellular level, which is a game-changer for those with obesity, a condition that goes beyond mere dietary habits and exercise routines

Definitely recommend

Double-Check the Syringe: If you are using compounded tirzepatide from a vial, always verify the volume you have drawn against your prescribed dose before injecting